Dose limiting extramedullary toxicity of high dose chemotherapy

Autologous marrow support may allow higher doses of myelosuppressive chemotherapy administration with the hope of improving tumor responses. The approach will be limited by the extramedullary toxicities of the drugs employed. This paper reviews some of these toxicities for selected drugs, and gives examples of techniques which could be used to reduce their incidence.